This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Amag: Hedge Fund Makes Takeover Bid

Updated with more information.

LEXINGTON, Mass. ( TheStreet) -- Hedge fund MSMB Capital made an unsolicited, $18-a-share offer for Amag Pharmaceuticals (AMAG - Get Report) as an alternative to Amag's previously announced plan to merge with Allos Therapeutics (ALTH).

The MSMB Capital offer represents a 25% premium to Amag's Aug. 2 closing share price of $14.39. Amag shares were up 11% to $16 in Wednesday pre-marketing trading.

"MSMB is a long-term investor in Amag and believes that the management's current strategy does not protect the interests of Amag's stockholders or ensure Amag's long-term viability. I believe that our offer is superior and more beneficial to Amag's stockholders than the proposed no-premium merger between Amag and Allos Therapeutics," said MSMB chief investment officer Martin Shkreli in a letter sent to Amag management.

Amag, in a statement, acknowledged receipt of the takeover proposal and said it would evaluate the offer.

On July 20, Amag announced plans to merge with Allos in an all-stock deal that valued Allos at $2.44 a share, or $260 million. Yet questions about the rationale behind the proposed deal left many investors and Amag shareholders puzzled, even angry.

Amag shares have lost 25% of their value since the July 20 merger proposal with Allos was made public. Even Allos shares have fallen 8%, suggesting the deal lacks shareholder support and stands a good chance of never being consummated.

Amag has struggled to market its iron replacement therapy Feraheme since approval and launch in July 2009. Likewise, sales of Allos' lymphoma drug Folotyn have been a major disappointment since FDA approved the drug in September 2009.

MSMB Capital, led by fund manager Shkreli, has ramped up shareholder activism in recent months. Shkreli has been public about shorting Neoprobe (NEOP) and even took the extraordinary step of filing a citizen's petition with the U.S. Food and Drug Administration seeking to stop the agency from reviewing Neoprobe's lymph-node mapping agent.

In June, MSMB Capital made an unsolicited takeover offer for SeraCare Life Sciences (SRLS). Following that proposal, Seracare's CEO resigned and the company announced it was putting itself up for sale.

One Amag shareholder, not affiliated with MSMB Capital and with no direct knowledge of the firm's offer, said he'd be willing to sell his Amag stake for $20 a share.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AMAG $52.07 2.70%
AAPL $126.60 -1.50%
FB $81.28 0.48%
GOOG $575.75 0.42%
TSLA $201.61 -0.41%

Markets

DOW 18,135.98 +39.08 0.22%
S&P 500 2,099.84 +1.31 0.06%
NASDAQ 4,978.3610 +11.22 0.23%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs